Yiviva Announces Dosing of First Patient in Phase 2b Study of First-Line YIV-906 Plus Sorafenib Combination Therapy in the Treatment of Hepatocellular Carcinoma

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs